Press Releases
iCAD Among the First to Validate its AI Cancer Detection Solutions with the NVIDIA AI Enterprise Software Suite
NVIDIA platform streamlines adoption, accelerates deployment of iCAD’s solutions in virtualized data centers NASHUA, N.H. – March 2, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it is among the first to validate its AI solutions with theNVIDIA®…
iCAD to Present at the 42nd Annual Cowen Health Care Conference
NASHUA, N.H., March 1, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual 42nd Annual Cowen Health Care Conference, taking place March 7-9, 2022. Stacey Stevens, President and CEO of iCAD, Inc….
iCAD Reports Financial Results For Fourth Quarter And Year Ended December 31, 2021
Launched ProFound AI® Risk, the world’s first clinical decision support tool for short term breast cancer risk estimation Demonstrated compelling survival data for the use of Xoft® Brain IORT in recurrent glioblastoma (GBM) as published in Surgical Neurology International Company to Host Conference Call & Webcast Today at 4:30 PM…
iCAD to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28
NASHUA, N.H., Feb. 14, 2022 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021, after the market close, and host a conference call…
iCAD to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
NASHUA, N.H., February 8, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022. Stacey Stevens, President and incoming…
iCAD’s Breast AI Platform Earns U.S. Department of Defense Authorization to Operate
Leading-edge breast cancer detection platform meets stringent U.S. government security thresholds required for use across military healthcare facilities NASHUA, N.H. – January 24, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company’s breast artificial intelligence…
iCAD Announces the Appointment of New Members to its Board of Directors
Dana Brown and Timothy Norris Irish offer extensive experience in technology, women’s breast health and unique global perspectives NASHUA, N.H., January 11, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today it has appointed Dana Brown and Timothy Norris…
iCAD Announces Estimated Q4 and Fiscal Year 2021 Revenues
Company expects preliminary estimated Q4 2021 revenues to be between $7.8-$8.0 million NASHUA, N.H., January 4, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the fourth quarter and full year of 2021. Based…
iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event
Company’s President and incoming CEO to participate in a panel discussion titled “Med Tech / Digital Tools: What’s the Mindset for 2022?” on January 5, 2022 at 2:00 pm ET NASHUA, N.H., Dec. 23, 2021 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection…
First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States
Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor Intriguing research supporting novel therapy approach recently published in peer-reviewed journal, Surgical Neurology International For the first time in the U.S.,…